Aortic valve replacement in pediatric patients: 30 years single center experience

• Main Authors: Johanna Schlein, Paul Simon, Gregor Wollenek, Eva Base, Günther Laufer, Daniel Zimpfer
• Format: Article
• Language: English
• Published: BMC 2021-09-01
• Series: Journal of Cardiothoracic Surgery
• Subjects: Congenital aortic valve disease; Pediatric aortic valve replacement; Pediatric mechanical aortic valve replacement; Pediatric homograft aortic valve replacement; Pediatric bioprosthetic aortic valve replacement
• Online Access: https://doi.org/10.1186/s13019-021-01636-2

Abstract Background The choice of aortic valve replacement needs to be decided in an interdisciplinary approach and together with the patients and their families regarding the need for re-operation and risks accompanying anticoagulation. We report long-term outcomes after different AVR options. Methods A chart review of patients aged < 18 years at time of surgery, who had undergone AVR from May 1985 until April 2020 was conducted. Contraindications for Ross procedure, which is performed since 1991 at the center were reviewed in the observed non-Ross AVR cohort. The study endpoints were compared between the mechanical AVR and the biological AVR cohort. Results From May 1985 to April 2020 fifty-five patients received sixty AVRs: 33 mechanical AVRs and 27 biological AVRs. In over half of the fifty-three AVRs performed after 1991 (58.5%; 31/53) a contraindication for Ross procedure was present. Early mortality was 5% (3/60). All early deaths occurred in patients aged < 1 year at time of surgery. Two late deaths occurred and survival was 94.5% ± 3.1% at 10 years and 86.4% ± 6.2% at 30 years. Freedom from aortic valve re-operation was higher (p < 0.001) in the mechanical AVR than in the biological AVR cohort with 95.2% ± 4.6% and 33.6% ± 13.4% freedom from re-operation at 10 years respectively. Conclusions Re-operation was less frequent in the mechanical AVR cohort than in the biological AVR cohort. For mechanical AVR, the risk for thromboembolic and bleeding events was considerable with a composite linearized event rate per valve-year of 3.2%.